Important note

This AI stock analysis for Intellia Therapeutics is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Intellia Therapeutics - AI Stock Analysis

Analysis generated November 20, 2024

Intellia Therapeutics is a biotech company that focuses on developing curative products leveraging CRISPR/Cas9 gene-editing technology. The organization aims to develop transformative medicines for severe diseases by using its modular genome editing and delivery platforms.

Fundamental Analysis

Revenue for the last quarter stands at $9.1M. This is an increase of 30.96% compared to the quarter before it, indicating positive quarter-over-quarter growth. However, compared to the same quarter last year, there is a decrease of 29.87%, which could be a concern for long-term sustainability.

Net income for the last quarter was $136M, marking an increase of 7.66% quarter-over-quarter. Nevertheless, compared to the same quarter last year, there's a decrease of 11.04%. Such metrics indicate that while the company is growing, it may still be facing some headwinds in maintaining profitability year over year.

EBITDA for the last quarter was $0. This is an improvement of 100.00% quarter-over-quarter and year-over-year, suggesting positive operational efficiencies and potential for future profitability.

Technical Analysis

Today's stock price is $12.99, representing a 38.38% decrease compared to a month ago and a 54.36% decrease from a year ago. These figures indicate potential short-term and long-term concerns for shareholders.

The current Simple Moving Average (SMA10) is 14.86, which is lower than the previous SMA10 of 15.23. This suggests a potential downward trend in price movement. The Relative Strength Index (RSI) stands at 60.6, indicating neutral market conditions but veering closer to the overbought territory.

Alternative Data Analysis

Intellia Therapeutics has 8 open positions as per data from popular job boards, down by 53% in the last couple of months. This reduction could signify efforts to cut costs or improve margins, a point of concern for a growing company.

The business outlook among employees at Intellia Therapeutics is 42% positive, indicating a relatively low level of confidence. However, this outlook has been trending upwards by 20% in the recent months, marking a positive shift in employee sentiment.

On the customer acquisition front, Intellia Therapeutics has an estimated 45,000 webpage visitors, up by 114% in the last couple of months. This bullish trend suggests potential customer growth.

Regarding customer engagement, Intellia Therapeutics has 1,200 Instagram followers and 11,000 Twitter followers, with no significant changes in the last couple of months. Altindex’s AI score for predicting the stock price is 46, which indicates a hold signal.

Conclusion

Intellia Therapeutics shows a mixed bag of metrics. While there are positive trends like revenue growth and increased webpage visitors, the significant decrease in stock price and low employee outlook raise concerns. However, the improvement in EBITDA and the rise in business outlook among employees are promising. Given the balanced pros and cons, it would be prudent to adopt a cautious approach and maintain a hold position on Intellia Therapeutics stock at this time.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.